Two CDMOs come together as they look to expand their reach in cell therapy manufacturing
As the cell therapy field has matured, the manufacturing of such therapies becomes a greater focus for companies small and large. Amid this growth, two CDMOs have come together in a merger to expand their reach.
Lykan Bioscience, based in Massachusetts, and RoslinCT, based in Edinburgh, UK, will become a single advanced therapies CDMO. The newly combined group will offer process development expertise as well as cGMP manufacturing for a broad range of autologous and allogeneic cell therapies, along with gene editing and induced pluripotent stem cell (iPSC) capabilities for cell therapy development. Financial terms of the deal were not disclosed.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.